The nephrologist’s guide to cannabis and cannabinoids Joshua L. Rein Purpose of review Cannabis (marijuana, weed, pot, ganja, Mary Jane) is the most commonly used federally illicit drug in the United States. The present review provides an overview of cannabis and cannabinoids with relevance to the practice of nephrology so that clinicians can best take care of patients. Recent findings Cannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-stage renal disease including as a pain adjuvant potentially reducing the need for opioids. Cannabis does not seem to affect kidney function in healthy individuals. However, renal function should be [...]
Lire la suiteDo medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers? Sharon R. Sznitman, Monica J. Barratt, Tom Decorte, Pekka Hakkarainen, Simon Lenton, Gary Potter, Bernd Werse and Chris Wilkins Drugs and Alcohol Today, 2019, 19, (4), 251-256, Doi : 10.1108/DAT-06-2019-0021 Abstract Purpose – It is conceivable that cannabis cultivators who grow for medical purposes aim to improve the therapeutic index of their cannabis by attempting to produce particular concentrations of CBD and/or THC. The purpose of this paper is to examine whether small-scalemedical cannabis growers differ fromthose growing for recreational reasons in terms of self-assessed concentrations of THC and CBD [...]
Lire la suiteInfection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique Roland Tubiana et Fabienne Caby, 24e Rencontres du RESPADD - GRECC, "Usages Cliniques des Cannabinoïdes" 21 juin 2019 (...) Inflammation/ Activation immune et CB Chez les PVVIH traités efficacement, la consommation de CB a été associée: – À des niveaux moins élevés de marqueurs d’inflammation (L B TNF-α+ )/ activation immune (L TCD4+ et CD8+ HLA-DR+CD38+) – A une décroissance plus rapide du niveau d’ADN proviralVIH Mécanismes sous jacents CB (Cannabis Sativa) : > 60 cannabinoides, > 200 non cannabinoides • Cannabinoides: Composant capables d’activer la proteine G couplée aux récepteurs CB1 ou CB2 • Les 2 plus étudiés: Δ9-THC [...]
Lire la suiteTotality of the Evidence Suggests Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments : A Systematic and Critical Review Ciara A. Torres, Christopher Medina-Kirchner, Kate Y. O'Malley and Carl L. Hardt Frontiers in Psychology, 2020, Vol 11, Art 816, 1-28. Doi : 10.3389/fpsyg.2020.00816 Background: Despite limited data demonstrating pronounced negative effects of prenatal cannabis exposure, popular opinion and public policies still reflect the belief that cannabis is fetotoxic. Methods: This article provides a critical review of results from longitudinal studies examining the impact of prenatal cannabis exposure on multiple domains of cognitive functioning in individuals aged 0 to 22 years. A literature search was [...]
Lire la suiteDeveloping Robust Standardised Analytical Procedures for Cannabinoid Quantification : Laying the Foundations for an Emerging Cannabis-Based Pharmaceutical Industry Matthew T. Welling, Lei Liu, Arno Hazekamp, Ashley Dowell, Graham J. King Medical Cannabis & Cannabinoids, 2019, 2, 1–13 Doi : 10.1159/000496868 Abstract The plant genus Cannabis is a prolific producer of unique pharmaceutically relevant metabolites, commonly referred to as cannabinoids. Robust and standardised methods for the quantification of cannabinoids within botanical and drug forms is a critical step forward for an emerging Cannabis- based pharmaceutical industry, which is poised for rapid expansion. Despite a growing body of analytical methods for the quantification of cannabinoids, few have [...]
Lire la suiteCannabinoids in Gynecological Diseases Petra Luschnig, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 14-21 Doi : 10.1159/000499164 Abstract The endocannabinoid system (ECS) is a multifunctional homeostatic system involved in many physiological and pathological conditions. The ligands of the ECS are the endocannabinoids, whose actions are mimicked by exogenous cannabinoids, such as phytocannabinoids and synthetic cannabinoids. Responses to the ligands of the ECS are mediated by numerous receptors like the classical cannabinoid receptors (CB1 and CB2) as well as ECS-related receptors, e.g., G protein-coupled receptors 18 and 55 (GPR18 and GPR55), transient receptor potential ion channels, and nuclear peroxisome proliferator-activated receptors. The ECS regulatesalmost all levels of [...]
Lire la suiteA Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers Daniel Perkins · Juliet Butler · Katherine Ong · Tri‑Hung Nguyen · Susan Cox · Barbara Francis · Michelle Mcintosh · Brian Lilley European Journal of Drug Metabolism and Pharmacokinetics, 2020, Doi : 10.1007/s13318-020-00624-6 Abstract Background : There is increasing interest in the use of purified cannabidiol (CBD) as a treatment for a wide range of conditions due to its reported anti-inflammatory, anxiolytic, antiemetic and anticonvulsant properties. Objective : The objective of this study was to assess the [...]
Lire la suiteThe Reemergence of Ketamine for Treatment in Critically Ill Adults Kimberly P. Hurth, Kristen B. Thomas, Michael A. Rudoni Critical Care Medicine, 2020,1-13. Doi : 10.1097/CCM.0000000000004335 Objectives : To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population. Data Sources : A literature review was performed using PubMed evaluating primary literature published until August 2018. Study Selection : Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of [...]
Lire la suiteThe Intricate Influence of the Placebo Effect on Medical Cannabis and Cannabinoids Jürg Gertsch Medical Cannabis Cannabinoids, 2018, 1, 60–64 Doi : 10.1159/000489291 Abstract The botanical drug cannabis flos (inflorescence of Cannabis sativa L.) has a unique popular status as being a potent recreational drug and bona fide universal remedy (panacea). Generally, cannabinoids exert therapeutic effects in a broad range of pathophysiologies related to inflammation, pain, metabolic and stress-related conditions in preclinical animal models. However, the translation of such data to humans still lacks an evidence-based foundation. Motivated by the booming cannabis manufacturing industry and the increasing worldwide self-therapy by patients, there are cumulative accounts [...]
Lire la suiteBeneficial Effects of Cannabis on Blood Brain Barrier Function in HIV Ronald J Ellis 1 , Scott Peterson 2 , Mariana Cherner 1 , Erin Morgan 1 , Rachel Schrier 1 , Bin Tang 1 , Martin Hoenigl 1 , Scott Letendre 1 , Jenny Iudicello 1 Clinical infectious diseases, 2020 Apr 16, ciaa437. Doi : 10.1093/cid/ciaa437 Abstract Background: HIV infection leads to blood-brain barrier (BBB) dysfunction that does not resolve despite viral suppression on antiretroviral therapy and is associated with adverse clinical outcomes. In preclinical models, cannabis restores BBB integrity. Methods: We studied people with HIV (PWH) and HIV- individuals who had used cannabis [...]
Lire la suite